Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Rhea-AI Summary
Celcuity (Nasdaq: CELC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, March 25, 2026. Management will host a webcast/teleconference at 4:30 p.m. ET the same day to discuss results and provide a corporate update.
Domestic dial-in is 1-800-717-1738, international dial-in is 1-646-307-1865, and a live webcast is available via the company link; a replay will be posted on Celcuity's website.
Positive
- None.
Negative
- None.
News Market Reaction – CELC
On the day this news was published, CELC declined 1.40%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CELC was down 0.69% while key biotech peers were mixed: CGON up 4.14%, IBRX down 8.01%, others near flat. Moves do not show a unified sector trend.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 scheduling | Neutral | +2.2% | Announced Q3 2025 results release date and post-close webcast details. |
| Aug 07 | Q2 2025 scheduling | Neutral | +0.1% | Set date and access details for Q2 2025 results and webcast. |
| May 07 | Q1 2025 scheduling | Neutral | +0.6% | Outlined timing and dial-in for Q1 2025 financial results call. |
| Mar 24 | FY 2024 scheduling | Neutral | +3.2% | Announced Q4 and full-year 2024 release with same-day webcast. |
| Nov 07 | Q3 2024 scheduling | Neutral | -3.2% | Scheduled Q3 2024 results release and webcast timing. |
Scheduling earnings/webcast dates has historically led to modest single-day moves, ranging from about -3.2% to +3.24% around similar announcements.
Over the past year, Celcuity has regularly issued releases scheduling quarter and year-end results with associated webcasts at 4:30 p.m. ET. These “conferences, earnings” notices for Q3 2024, Q4 2024, and the 2025 quarterly results typically outlined post-close releases and standard dial-in details. Price reactions spanned small gains and losses around these routine updates. Today’s announcement continues that pattern by setting timing for Q4 and full year 2025 results and a same-day webcast and conference call.
Historical Comparison
Past “conferences,earnings” scheduling releases moved CELC by an average of 0.59%, suggesting typically modest reactions to similar timing updates.
The company has consistently pre-announced quarterly and annual results with standard 4:30 p.m. ET webcasts, and this Q4/full-year 2025 notice continues that established pattern.
Regulatory & Risk Context
An effective S-3ASR shelf with an at-the-market program permits Celcuity to offer up to $400,000,000 of common stock and other securities over time, providing flexible capital-raising capacity alongside ongoing clinical and commercial plans for gedatolisib.
Market Pulse Summary
This announcement sets expectations for the release of fourth quarter and full year 2025 results and a same-day webcast at 4:30 p.m. ET. Historically, similar scheduling notices under the “conferences,earnings” tag have produced only modest single-day moves, with an average reaction of about 0.59%. Investors may focus on how upcoming results intersect with Celcuity’s clinical progress and its effective $400,000,000 shelf and at-the-market program when the detailed financials and corporate update are provided.
AI-generated analysis. Not financial advice.
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1751140&tp_key=9ff20687c4. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer (“ABC”), has completed enrollment, and the company has reported detailed results for the PIK3CA wild-type cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with endocrine resistant HR+/HER2- ABC, is ongoing. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924
FAQ
When will Celcuity (CELC) release Q4 and full year 2025 results?
How can investors join the Celcuity (CELC) webcast/teleconference on March 25, 2026?
Will a replay of the Celcuity (CELC) March 25, 2026 webcast be available?
What topics will Celcuity (CELC) management address in the March 25, 2026 call?
Is there a direct webcast link to join Celcuity's (CELC) March 25, 2026 presentation?
Are international callers able to join the Celcuity (CELC) teleconference on March 25, 2026?
